Terns' CML drug is an allosteric inhibitor, targeting a different site on the target protein than older drugs. This mechanism provides greater selectivity, avoiding off-target effects like arterial blockages common with active-site inhibitors. This technical advantage creates a compelling safety and tolerability profile, a key differentiator in a market with established therapies.

Where Lilly pursued a challenging medicinal chemistry approach to make a drug more specific, PureTech's Karuna succeeded with a simpler biological solution. They paired the drug with an existing one that blocked its effects outside the brain, mitigating side effects without altering the core, promising molecule.

CEO Dan Schmitt outlines a three-part test for a new drug: it must effectively engage its intended biological target, avoid interacting with other enzymes to prevent toxicity, and be deliverable to a patient in sufficient quantities to be effective. This framework simplifies the core challenges of drug development.

Tirzepatide is a rare "once in a blue moon" drug because it is both more potent and better tolerated than its main competitor. This paradoxical profile—achieving superior efficacy with fewer side effects—has established it as the "king of the hill" in the obesity market and created an extremely high bar for any challenger.

Eikon's strategy for its PARP inhibitor wasn't just to create a better version of an existing drug class, but one with superior combinability. By selectively targeting PARP1, they minimized the hematologic toxicity that prevented older PARP inhibitors from being used with chemotherapies like taxanes, opening up earlier lines of treatment.

When comparing drugs with the same mechanism, like Alkermes' and Takeda's orexin agonists, a wider therapeutic index is a crucial differentiator. This superior safety-to-efficacy ratio allows for higher, more effective dosing without significant side effects, creating a competitive advantage and potential for broader market use.

Acknowledging its late entry into the crowded obesity market, Protagonist consulted key opinion leaders to define the ideal drug profile: an oral "triple G" agonist. By using its peptide platform to build exactly what experts requested, the company aims to leapfrog competitors with a best-in-class product rather than an incremental improvement.

Actuate’s drug was designed to be highly lipophilic (fat-soluble) to cross the blood-brain barrier for CNS treatment. This same property proved crucial for its success in oncology, as it allows the drug to easily penetrate cancer cell membranes and reach the nucleus.

Xenon successfully de-risked the biologically validated but previously failed KV7 epilepsy target. They designed a new chemical structure that prevents dimerization, the molecular action responsible for the severe side effects that caused GSK's earlier drug to be withdrawn. This showcases a strategy of innovating on chemistry to solve known safety issues of a proven mechanism.